Authors' reply to Wardlaw and Berge

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Alper, Brian S ^a   Malone Moses, Meghan ^a   McLellan, James S ^a   Prasad, Kameshwar ^b   Manheimer, Eric ^c  

^a EBSCO Industries Inc   (United States)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c Bahrain Branch of the Cochrane Collaboration   (Bahrain)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CLINICAL EFFECTIVENESS; DRUG EFFICACY; HUMAN; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLICATION; RANDOMIZATION; RISK ASSESSMENT; EVIDENCE BASED MEDICINE; FIBRINOLYTIC THERAPY; STROKE;

EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HUMANS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84928038699     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h1795     Document Type: Letter

References (5)

1. Wardlaw JK, Berge E. Cochrane reviewers' response to Alper and colleagues' analysis of thrombolysis in acute ischaemic stroke. BMJ 2015;350:h1790.
2. Wardlaw JM, Murray V, Berge E, et al. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2014;7:CD000213.
3. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-29.
4. Alper BS, Malone-Moses M, McLellan JS, et al. Thrombolysis in acute ischaemic stroke: time for a rethink? BMJ 2015;350:h1075. (17 March.)
5. Shy BD. Implications of ECASS III error on emergency department treatment of ischemic stroke. J Emerg Med 2014;46:385-6.